Showing results (1-10 of 126) with videos related to
Sort By:
Pageof 13
British Journal of Haematology|December 2, 2024
Clinical perspectives on post-induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantationKendra Sweet, Thomas CluzeauBulletin Du Cancer|September 28, 2015
[Management of myelodysplastic syndromes]Matthieu Duchmann, Pierre Fenaux, Thomas CluzeauCancers|September 23, 2022
How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic SyndromesMichael Loschi, Pierre Fenaux, Thomas CluzeauCurrent Pharmaceutical Design|February 12, 2013
How recent advances in high-risk myelodysplastic syndrome physiopathology may impact future treatmentsThomas Cluzeau, Guillaume Robert, Arnaud Jacquel, et al.Current Hematologic Malignancy Reports|April 1, 2014
Pediatric-like therapy for adults with ALLHervé Dombret, Thomas Cluzeau, Françoise Huguet, et al.International Journal of Molecular Sciences|June 2, 2021
FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic ReviewMichael Loschi, Rinzine Sammut, Edmond Chiche, et al.Clinical Case Reports|January 26, 2026
Digenic Functional B12 and Folate Defect Mimicking MyelodysplasiaThomas Cluzeau, Abderrahim Oussalah, Maël Silva Rodriguez, et al.Cancers|March 10, 2022
Measurable Residual Disease in High-Risk Acute Myeloid LeukemiaThomas Cluzeau, Roberto M Lemoli, James McCloskey, et al.Frontiers in Oncology|July 6, 2016
Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS PhenotypeDavid A Sallman, Thomas Cluzeau, Ashley A Basiorka, et al.Cancers|May 25, 2024
Relapse Prevention in Acute Myeloid Leukemia: The Role of Immunotherapy with Histamine Dihydrochloride and Low-Dose Interleukin-2Pau Montesinos, Francesco Buccisano, Thomas Cluzeau, et al.Pageof 13